COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02745184
Recruitment Status : Recruiting
First Posted : April 20, 2016
Last Update Posted : March 26, 2020
Regend Therapeutics
Information provided by (Responsible Party):
Wei Zuo, Shanghai East Hospital

Brief Summary:
Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal disease characterized by a progressive damage of lung structure and decline in lung function.This study intends to carry out an open, single-center, non-randomized, self control phase I clinical trial. During the treatment, lung stem cells will be isolated from patients' own bronchi and expanded in vitro. Cultured cells will be injected directly into the lesion by fiberoptic bronchoscopy after lavage. After twelve-month observation, the investigators will evaluate the safety and efficacy of the treatment by measuring the key clinical indicators.

Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis Biological: Lung stem cells Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Actual Study Start Date : April 2016
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : October 2021

Arm Intervention/treatment
Experimental: lung stem cells
Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
Biological: Lung stem cells
Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.

Primary Outcome Measures :
  1. Changes in forced vital capacity (FVC) [ Time Frame: 48 weeks ]
    To evaluate changes in FVC from baseline to 48 weeks

Secondary Outcome Measures :
  1. Changes in Forced expiratory volume in one second (FEV1) [ Time Frame: 48 weeks ]
  2. The differences of diffusing capacity of the lung for carbon monoxide (DLco) [ Time Frame: 48 weeks ]
  3. Changes in 6 minute walk distance (6MWD) [ Time Frame: 48 weeks ]
  4. Life quality: assessed by St. George respiratory questionnaire (SGRQ) [ Time Frame: 48 weeks ]
  5. Dyspnea score according by Modified Medical Research Center(MMRC) [ Time Frame: 48 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1)Written informed consent signed; 2)40<Age<=75 years; 3)Clinically diagnosed idiopathic pulmonary fibrosis(see 2011 guidance);

Exclusion Criteria:

  1. Allergic to cell therapy;
  2. Patients with serious significant pulmonary infection need anti-infection treatment;
  3. Patients who has taken amiodarone which may cause pulmonary fibrosis in the past 3 months;
  4. Patients with malignant tumor in the past 5 years;
  5. Participated in other clinical trials in the past 3 months;
  6. Patients with serious heart disease(NYHA class Ⅲ-Ⅳ), liver disease(ALT or AST 2 times above the upper level of normal value range), kidney disease(Cr above the upper level of normal value range);
  7. Pregnant or lactating women;
  8. The investigator assessed as inappropriate to participate in this clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02745184

Layout table for location contacts
Contact: Tao Ren, M.D.
Contact: Wei Zuo, Ph.D.

Layout table for location information
China, Jiangsu
Regend Therapeutics Recruiting
Suzhou, Jiangsu, China, 215123
Contact: Wei Zuo, Ph.D.   
Contact: Ting Zhang, Ph.D.   
Principal Investigator: Wei Zuo, Ph.D.         
Sub-Investigator: Ting Zhang, Ph.D.         
Sub-Investigator: Yu Ma, Ph.D.         
China, Shanghai
Shanghai East Hospital Recruiting
Shanghai, Shanghai, China, 200123
Contact: Tao Ren, M.D.   
Contact: Lihua Bai, M.M.   
Principal Investigator: Tao Ren, M.D.         
Sponsors and Collaborators
Shanghai East Hospital
Regend Therapeutics
Layout table for additonal information
Responsible Party: Wei Zuo, Professor, Shanghai East Hospital Identifier: NCT02745184    
Other Study ID Numbers: 201602101
First Posted: April 20, 2016    Key Record Dates
Last Update Posted: March 26, 2020
Last Verified: March 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Idiopathic Interstitial Pneumonias
Lung Diseases, Interstitial